Cincinnati Business Courier: UC makes dean for College of Medicine official

Andrew Filak, MD, leads medical school as bicentennial approaches

Cincinnati Business Courier reports the University of Cincinnati has named Dr. Andrew Filak, Jr., dean of the College of Medicine and senior vice president for health affairs. Filak, who has been serving in the role on an interim basis since August 2018, will officially assume the position January 1, 2020, pending approval by the UC Board of Trustees.  Filak will oversee a medical college consisting off 25 departments with about 2,500 employees and almost 1,700 students. A 2016 UC Economics Center study concluded the College of Medicine has an economic impact of about $ 1billion in the region.

Filak has more than four decades of experience at the UC College of Medicine, UC Medical Center, and the UC Academic Heath Center. Prior to his position as interim dean, Dr. Filak served as senior associate dean for academic affairs, founding chair of the Department of Medical Education and professor of medical education and family and community medicine at the UC College of Medicine. He also served as vice president for education for UC Health.

Read the Business Courier story online

Learn more about Dr. Filak online

Related Stories

1

Recent advances may speed time to endometriosis diagnosis

March 16, 2026

The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.

3

Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy

March 16, 2026

Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.